TP53 and neoplasm: Interestingly, we detected the TP53 mutation p. R342* in circulating tumor DNA (ctDNA) plasma samples collected before surgery (T0, VAF 1%) and 2 months before clinical evidence of skeletal metastatic lesion development (T4, VAF 0.3%).